X-linked Alport syndrome is a hereditary disease caused by pathogenic variants in COL4A5. It is usually more severe in males, while females present with variable clinical expression. The alteration of the alpha-5 chain of type IV collagen compromises the glomerular basement membrane and causes progressive nephropathy, which can be associated with sensorineural hearing loss and ocular abnormalities.
X-linked Alport syndrome
COL4A5 encodes the alpha-5 chain of type IV collagen, which assembles with alpha-3 and alpha-4 chains. The resulting heterotrimer forms an essential structural network of the glomerular basement membrane and specialized membranes of the cochlea and eye.
Pathogenic variants alter the synthesis or assembly of this network, causing thinning, irregular thickening, and lamination of the glomerular basement membrane. Hemicygous males typically progress more rapidly. In heterozygous females, variable X chromosome inactivation contributes to a spectrum ranging from isolated hematuria to kidney disease. An affected female transmits the variant in 50% of pregnancies; an affected male transmits it to all of his daughters and none of his sons. The precise clinical frequency is uncertain; genomic estimates place pathogenic COL4A5 variants at approximately 1 in 2,320 individuals.
Symptoms
Persistent microscopic hematuria usually appears from childhood. In males, proteinuria usually develops, followed by hypertension, renal deterioration, and end-stage renal disease; the speed of progression depends partly on the type of variant. Bilateral sensorineural hearing loss is not congenital and is usually detected in late childhood or during adolescence. Anterior lenticonus and retinal abnormalities may also appear, especially in severe phenotypes. Women usually progress more slowly, but some develop proteinuria, hearing loss, and chronic kidney disease in adulthood.
Disease management
There is no curative treatment that restores the normal network of type IV collagen. Management includes nephrological follow-up with control of albuminuria or proteinuria, blood pressure, and renal function. Early blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists delays progression and should be individualized according to age and clinical situation. Auditory and ocular monitoring, avoidance of nephrotoxins, and study of at-risk family members are also recommended. Dialysis and kidney transplantation are used in end-stage disease; post-transplant anti-glomerular basement membrane nephritis is infrequent. New nephroprotective strategies are being investigated, but none currently correct the genetic defect.
Genes analyzed
Bibliography
Nozu K, Yamamura T, Horinouchi T. Alport Syndrome. GeneReviews®. 2025 update.
Torra R, Lipska-Zietkiewicz B, Acke F, et al. Diagnosis, management and treatment of Alport syndrome: 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025;40(6):1091-1106.
Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for Genetic Testing and Management of Alport Syndrome. Clin J Am Soc Nephrol. 2022;17(1):143-154.
Suzuki R, Sakakibara N, Murakami S, et al. Genotype and X-chromosome inactivation are associated with disease severity in females with X-linked Alport syndrome. Nephrol Dial Transplant. 2025;40(4):688-695.
